Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL517093 | 1.00 | ALOX5 (0.39) | ALOX5HDAC6MAOBCYP2D6CHRM3 | |
| SCHEMBL1079340 | 0.94 | MAOB (0.37) | MAOBCYP2D6CHRM3KMT2AC3AR1 | |
| SCHEMBL1177991 | 0.92 | MAOB (0.40) | ALOX5HDAC6MAOBKMT2AC3AR1 | |
| SCHEMBL1177731 | 0.91 | C3AR1 (0.37) | ALOX5HDAC6MAOBKMT2AC3AR1 | |
| SCHEMBL3705337 | 0.91 | MAOB (0.43) | MAOBKMT2A | |
| Bicarbonate SCHEMBL3693977 | 0.89 | C3AR1 (0.45) | KMT2AC3AR1 | |
| SCHEMBL3696998 | 0.89 | CYP2D6 (0.41) | ALOX5HDAC6MAOBCYP2D6CHRM3 | |
| SCHEMBL12871474 | 0.88 | KMT2A (0.35) | MAOBCYP2D6CHRM3KMT2A | |
| SCHEMBL517046 | 0.87 | CYP3A4 (0.36) | MAOBCYP2D6CHRM3KMT2A | |
| Bicarbonate SCHEMBL1079990 | 0.87 | BDKRB2 (0.43) | CYP2D6KMT2AC3AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987256-B2 | Oxo-heterocyclic substituted carboxylic acid derivatives and the use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-03-24 | — | — | US | disclosed |
| EP-2268625-B1 | OXO-HETEROCYCLIC SUBSTITUTED CARBOXYLIC ACID DERIVATES AND THE USE THEREOF | Bayer Pharma AG (DE) | 2012-05-16 | — | — | EP | disclosed |
| US-20110034450-A1 | OXO-HETEROCYCLIC SUBSTITUTED CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIEGESELLSCHAFT (DE) | 2011-02-10 | — | — | US | disclosed |
| EP-2268625-A1 | OXO-HETEROCYCLIC SUBSTITUTED CARBOXYLIC ACID DERIVATES AND THE USE THEREOF | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009127338-A1 | OXO-HETEROCYCLIC SUBSTITUTED CARBOXYLIC ACID DERIVATES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034450-A1 | OXO-HETEROCYCLIC SUBSTITUTED CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF | OTC, PC, HCAR2 | ALOX5 94/4885HDAC6 771/4885MAOB 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.